Rahul Chaudhary, Facp

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3964359/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	PCSK9 inhibitors: A new era of lipid lowering therapy. World Journal of Cardiology, 2017, 9, 76.	1.5	200
2	Gut Microbial Dysbiosis in the Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Case-Control Studies. Journal of the Academy of Nutrition and Dietetics, 2020, 120, 565-586.	0.8	106
3	Role of gut microbiota in cardiovascular diseases. World Journal of Cardiology, 2020, 12, 110-122.	1.5	96
4	Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system. Journal of Thrombosis and Thrombolysis, 2017, 43, 437-445.	2.1	63
5	Direct oral anticoagulants: a review on the current role and scope of reversal agents. Journal of Thrombosis and Thrombolysis, 2020, 49, 271-286.	2.1	52
6	Thromboinflammatory Biomarkers in COVID-19: Systematic Review and Meta-analysis of 17,052 Patients. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2021, 5, 388-402.	2.4	51
7	Surgical Sepsis and Organ Crosstalk: The Role of the Kidney. Journal of Surgical Research, 2011, 167, 306-315.	1.6	49
8	Percutaneous Coronary Intervention in Older Patients With ST-Segment Elevation Myocardial Infarction and Cardiogenic Shock. Journal of the American College of Cardiology, 2019, 73, 1890-1900.	2.8	45
9	Therapeutic Hypothermia and StentÂThrombosis. JACC: Cardiovascular Interventions, 2016, 9, 1801-1811.	2.9	34
10	Personalizing Antithrombotic Therapy in COVID-19: Role of Thromboelastography and Thromboelastometry. Thrombosis and Haemostasis, 2020, 120, 1594-1596.	3.4	33
11	Timing of venous thromboembolism diagnosis in hospitalized and non-hospitalized patients with COVID-19. Thrombosis Research, 2021, 207, 150-157.	1.7	24
12	On-X Valve. Cardiology in Review, 2017, 25, 77-83.	1.4	22
13	Bilirubin in coronary artery disease: Cytotoxic or protective?. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2016, 7, 469.	1.1	22
14	Ivabradine. Journal of Cardiovascular Pharmacology and Therapeutics, 2016, 21, 335-343.	2.0	20
15	Antiplatelet Effect Durability of a Novel, 24-Hour, Extended-Release Prescription Formulation of Acetylsalicylic Acid in Patients With Type 2 Diabetes Mellitus. American Journal of Cardiology, 2016, 118, 1941-1947.	1.6	17
16	Race-Related disparities in COVID-19 thrombotic outcomes: Beyond social and economic explanations. EClinicalMedicine, 2020, 29-30, 100647.	7.1	17
17	Role of Prophylactic Magnesium Supplementation in Prevention of Postoperative Atrial Fibrillation in Patients Undergoing Coronary Artery Bypass Grafting: a Systematic Review and Meta-Analysis of 20 Randomized Controlled Trials Journal of Atrial Fibrillation, 2019, 12, 2154.	0.5	17
18	Risk factors associated with plasma omega-3 fatty acid levels in patients with suspected coronary artery disease. Prostaglandins Leukotrienes and Essential Fatty Acids, 2016, 113, 40-45.	2.2	16

RAHUL CHAUDHARY, FACP

#	Article	IF	CITATIONS
19	Combination oral antithrombotic therapy for the treatment of myocardial infarction: recent developments. Expert Opinion on Pharmacotherapy, 2018, 19, 653-665.	1.8	15
20	"Blueprinting―thrombogenicity and antithrombotic drug response at the bedside in patients presenting emergently with symptoms of acute stroke. Journal of Thrombosis and Thrombolysis, 2019, 47, 192-199.	2.1	14
21	Gender differences in thrombogenicity among patients with angina and non-obstructive coronary artery disease. Journal of Thrombosis and Thrombolysis, 2019, 48, 373-381.	2.1	14
22	Viscoelastic properties of clot formation and their clinical impact in East Asian versus Caucasian patients with stable coronary artery disease: a COMPARE-RACE analysis. Journal of Thrombosis and Thrombolysis, 2021, 51, 454-465.	2.1	14
23	Thrombinâ€Induced Plateletâ€Fibrin Clot Strength Identified by Thrombelastography. Journal of Interventional Cardiology, 2016, 29, 168-178.	1.2	13
24	Effects of vorapaxar on clot characteristics, coagulation, inflammation, and platelet and endothelial function in patients treated with mono―and dualâ€antiplatelet therapy. Journal of Thrombosis and Haemostasis, 2020, 18, 23-35.	3.8	13
25	Effect of serum zinc and copper levels on insulin secretion, insulin resistance and pancreatic β cell dysfunction in US adults: Findings from the National Health and Nutrition Examination Survey (NHANES) 2011–2012. Diabetes Research and Clinical Practice, 2021, 172, 108627.	2.8	13
26	Bedside thromboelastography to rapidly assessÂthe pharmacodynamic response of anticoagulants and aspirin in COVID-19: evidence of inadequate therapy in a predominantly minority population. Journal of Thrombosis and Thrombolysis, 2021, 51, 902-904.	2.1	13
27	Low-density lipoprotein 4: a novel predictor of coronary artery disease severity. Current Medical Research and Opinion, 2017, 33, 1979-1984.	1.9	11
28	Thirty-day readmissions after cardiac implantable electronic devices in the United States: Insights from the Nationwide Readmissions Database. Heart Rhythm, 2018, 15, 708-715.	0.7	11
29	First In-Human Experience With Inhaled Acetylsalicylic Acid for Immediate Platelet Inhibition. Circulation, 2020, 142, 1305-1307.	1.6	11
30	Macrovascular Thrombotic Events in a Mayo Clinic Enterprise-Wide Sample of Hospitalized COVID-19–Positive Compared With COVID-19–Negative Patients. Mayo Clinic Proceedings, 2021, 96, 1718-1726.	3.0	11
31	Cryoballoon versus Radiofrequency Ablation for Atrial Fibrillation: A Meta-analysis of 16 Clinical Trials. Journal of Atrial Fibrillation, 2016, 9, 1429.	0.5	11
32	Statin therapy and inflammation in patients with diabetes treated with high dose aspirin. Journal of Diabetes and Its Complications, 2016, 30, 1365-1370.	2.3	10
33	Role of implantable cardioverter defibrillator in non-ischemic cardiomyopathy: a systematic review and meta-analysis of prospective randomized clinical trials. Journal of Interventional Cardiac Electrophysiology, 2017, 49, 263-270.	1.3	10
34	His Bundle Pacing. Cardiology in Review, 2018, 26, 201-206.	1.4	10
35	Predictors of 30-day readmissions after catheter ablation for atrial fibrillation in the USA. Journal of Interventional Cardiac Electrophysiology, 2019, 55, 243-250.	1.3	10
36	Vorapaxar in the treatment of cardiovascular diseases. Future Cardiology, 2020, 16, 373-384.	1.2	10

#	Article	IF	CITATIONS
37	Detailed thrombogenicity phenotyping and 1 year outcomes in patients undergoing WATCHMAN implantation: (TARGET-WATCHMAN) a case–control study. Journal of Thrombosis and Thrombolysis, 2020, 50, 484-498.	2.1	10
38	Oxidized Low-Density Lipoprotein-β2-Glycoprotein I Complex But Not Free Oxidized LDL Is Associated With the Presence and Severity of Coronary Artery Disease. American Journal of Cardiology, 2016, 118, 673-678.	1.6	9
39	Naltrexone Initiation in the Inpatient Setting for Alcohol Use Disorder: A Systematic Review of Clinical Outcomes. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2021, 5, 495-501.	2.4	9
40	Central aortic pulse pressure, thrombogenicity and cardiovascular risk. Journal of Thrombosis and Thrombolysis, 2017, 44, 223-233.	2.1	8
41	Investigational drugs in phase II clinical trials for acute coronary syndromes. Expert Opinion on Investigational Drugs, 2020, 29, 33-47.	4.1	8
42	Safety And Efficacy Of Uninterrupted Periprocedural Apixaban In Patients Undergoing Atrial Fibrillation Catheter Ablation: A Metaanalysis Of 1,057 Patients. Journal of Atrial Fibrillation, 2016, 8, 1368.	0.5	8
43	Carotid access for transcatheter aortic valve replacement: A metaâ€analysis. Catheterization and Cardiovascular Interventions, 2021, 97, 723-733.	1.7	7
44	DOACs Versus VKAs in Older Adults Treated for Acute Venous Thromboembolism: Systematic Review and Metaâ€Analysis. Journal of the American Geriatrics Society, 2020, 68, 2021-2026.	2.6	7
45	Safety and efficacy of uninterrupted periprocedural rivaroxaban in patients undergoing atrial fibrillation catheter ablation: A metaanalysis of 1,362 patients. International Journal of Cardiology, 2016, 203, 906-908.	1.7	6
46	Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease. Expert Opinion on Pharmacotherapy, 2017, 18, 123-131.	1.8	6
47	HDL3-C is a Marker of Coronary Artery Disease Severity and Inflammation in Patients on Statin Therapy. Cardiovascular Revascularization Medicine, 2019, 20, 1001-1006.	0.8	6
48	Role of Internal Jugular Venous Ultrasound in suspected or confirmed Heart Failure: A Systematic Review. Journal of Cardiac Failure, 2022, 28, 639-649.	1.7	6
49	Safety and efficacy of oral factor-Xa inhibitors versus Vitamin K antagonist in patients with non-valvular atrial fibrillation: Meta-analysis of phase II and III randomized controlled trials. International Journal of Cardiology, 2016, 218, 235-239.	1.7	5
50	Association of weight gain with coronary artery disease, inflammation and thrombogenicity. Journal of Thrombosis and Thrombolysis, 2016, 41, 394-403.	2.1	5
51	Right ventricular apical versus non-apical implantable cardioverter defibrillator lead: A systematic review and meta-analysis. Journal of Electrocardiology, 2017, 50, 591-597.	0.9	5
52	Venous Thromboembolism Prophylaxis: Inadequate and Overprophylaxis When Comparing Perceived Versus Calculated Risk. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2017, 1, 242-247.	2.4	5
53	Thrombogenicity and central pulse pressure to enhance prediction of ischemic event occurrence in patients with established coronary artery disease: The MAGMA-ischemia score. Atherosclerosis, 2018, 268, 55-62.	0.8	5
54	Cangrelor for the treatment of patients with Arterial Thrombosis. Expert Opinion on Pharmacotherapy, 2018, 19, 1389-1398.	1.8	5

#	Article	IF	CITATIONS
55	Heart Failure Trial Update—Analysis of Recent Data. Journal of Cardiothoracic and Vascular Anesthesia, 2021, 35, 2792-2800.	1.3	5
56	BRASH: Case Report and Review of Literature. Hearts, 2021, 2, 302-306.	0.9	5
57	Improving Outcomes in Cardiovascular Diseases. Cardiology in Review, 2021, Publish Ahead of Print, .	1.4	4
58	Deep Vein Thrombosis after COVID-19 Vaccinations. Blood, 2021, 138, 291-291.	1.4	4
59	Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events. Expert Review of Cardiovascular Therapy, 2016, 14, 779-791.	1.5	3
60	Venous Thromboembolism Prophylaxis: Need for Continuous Assessment Due to Changes in Risk During the Same Hospitalization. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2020, 4, 170-175.	2.4	2
61	Telemetry: appropriateness of initial assignment and duration in nonintensive setting. American Journal of Managed Care, 2020, 26, 459-460.	1.1	2
62	Rivaroxaban-induced hemorrhagic pericardial tamponade in end-stage renal disease. Journal of Thrombosis and Thrombolysis, 2020, 50, 982-983.	2.1	1
63	Abstract 16676: Heightened Platelet Function: An Unrecognized Component of the Covid Hypercoagulability State. Circulation, 2020, 142, .	1.6	1
64	Erythropoietin therapy after out-of-hospital cardiac arrest: A systematic review and meta-analysis. World Journal of Cardiology, 2017, 9, 830-837.	1.5	1
65	Demystifying airline syncope. World Journal of Cardiology, 2020, 12, 107-109.	1.5	1
66	Coronary Artery Disease in Patients With Disorders of Bilirubin Excretion. American Journal of Therapeutics, 2017, 24, e653-e658.	0.9	0
67	Reply. JACC: Cardiovascular Interventions, 2017, 10, 105-106.	2.9	0
68	In search for an optimal antithrombotic regimen in patients with atrial fibrillation undergoing stenting. Kardiologia Polska, 2019, 77, 817-819.	0.6	0
69	Six Sigma approach to reduce door-to-balloon time for patients with STEMI. American Journal of Managed Care, 2020, 26, e140-e141.	1.1	Ο